Delving into the Latest Updates on LPM787000048 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LPM787000048, LY03020

Target

5-HT2C receptor x TAAR1

Action

agonists

Mechanism

5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists), TAAR1 agonists(Trace amine-associated receptor 1 agonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

SchizophreniaAcute schizophreniaAlzheimer Disease

Inactive Indication-

Originator Organization

Shandong Luye Pharmaceutical Co., Ltd.

Active Organization

Luye Pharma Group Ltd.

Shandong Luye Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

A Randomized, Double-Blind, Placebo-Controlled, Dose- Ascending Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Chinese Adult Healthy Subjects and/or Subjects With Stable Schizophrenia

This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.

Start Date20 Aug 2025

Sponsor / Collaborator

Luye Pharma Group Ltd.

NCT07292233

/ Active, not recruitingPhase 1

A Randomized, Open-Label, Single-Dose, Two-Period, Crossover Phase I Clinical Study to Evaluate the Food Effect on the Pharmacokinetics of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Healthy Subjects

This is a randomized, open-label, single-dose, two-period, crossover study to assess the food effect on pharmacokinetics (PK) and safety of LY03020 in healthy subjects.

Start Date30 Jul 2025

Sponsor / Collaborator

Luye Pharma Group Ltd.

NCT06556966

/ CompletedPhase 1

A Phase Ⅰ, Randomized, Double-blind, Placebo-controlled, Single Dose Ascending Study to Assess the Safety, Tolerability, and Pharmacokinetics of LPM787000048 Maleate Sustained-release Tablet (LY03020) in Chinese Healthy Adult Subjects

This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.

Start Date19 Aug 2024

Sponsor / Collaborator

Luye Pharma Group Ltd.

100 Clinical Results associated with LPM787000048

Login to view more data

100 Translational Medicine associated with LPM787000048

Login to view more data

100 Patents (Medical) associated with LPM787000048

Login to view more data

100 Deals associated with LPM787000048

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizophrenia	Phase 2	China	Luye Pharma Group Ltd.	31 Mar 2026
Acute schizophrenia	Phase 2	China	Shandong Luye Pharmaceutical Co., Ltd.	15 Jan 2026
Alzheimer Disease	Phase 1	China	Luye Pharma Group Ltd.	19 Aug 2024